Literature DB >> 34358439

Deep computational analysis details dysregulation of eukaryotic translation initiation complex eIF4F in human cancers.

Su Wu1, Gerhard Wagner2.   

Abstract

eIF4F plays diverse roles in human cancers, which complicate the development of an overarching understanding of its functional and regulatory impacts across tumor types. Typically, eIF4F drives initiation from the mRNA 5' end (cap) and is composed of eIF4G1, eIF4A1, and cap-binding eIF4E. Cap-independent initiation is possible without eIF4E, from internal ribosomal entry sites (IRESs). By analyzing large public datasets, we found that cancers selectively overexpress EIF4G1 more than EIF4E. That expression imbalance supports EIF4G1 as a prognostic indicator in patients with cancer. It also attenuates "housekeeping" pathways that are usually regulated in a tissue-specific manner via cap-dependent initiation in healthy tissues and reinforce regulation of cancer-preferred pathways in cap-independent contexts. Cap-independent initiation is mechanistically attributable to eIF4G1 hyperphosphorylation that promotes binding to eIF4A1 and reduced eIF4E availability. Collectively, these findings reveal a novel model of dysregulated eIF4F function and highlight the clinical relevance of cap-(in)dependent initiation in cancer.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RNA-sequencing; cap-independent translation initiation; computational analysis; eIF4F; eukaryotic initiation factor; human cancers; prognostic gene expression; protein interaction; translation dysregulation; translation initiation

Mesh:

Substances:

Year:  2021        PMID: 34358439      PMCID: PMC8460614          DOI: 10.1016/j.cels.2021.07.002

Source DB:  PubMed          Journal:  Cell Syst        ISSN: 2405-4712            Impact factor:   11.091


  87 in total

1.  c-Myc and eIF4F are components of a feedforward loop that links transcription and translation.

Authors:  Chen-Ju Lin; Regina Cencic; John R Mills; Francis Robert; Jerry Pelletier
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

2.  Detection of eIF4E gene amplification in breast cancer by competitive PCR.

Authors:  D L Sorrells; D R Black; C Meschonat; R Rhoads; A De Benedetti; M Gao; B J Williams; B D Li
Journal:  Ann Surg Oncol       Date:  1998 Apr-May       Impact factor: 5.344

Review 3.  Is Myc an Important Biomarker? Myc Expression in Immune Disorders and Cancer.

Authors:  Shivtia Trop-Steinberg; Yehudit Azar
Journal:  Am J Med Sci       Date:  2017-06-15       Impact factor: 2.378

4.  Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism.

Authors:  A C Gingras; S P Gygi; B Raught; R D Polakiewicz; R T Abraham; M F Hoekstra; R Aebersold; N Sonenberg
Journal:  Genes Dev       Date:  1999-06-01       Impact factor: 11.361

5.  The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.

Authors:  David Shahbazian; Philippe P Roux; Virginie Mieulet; Michael S Cohen; Brian Raught; Jack Taunton; John W B Hershey; John Blenis; Mario Pende; Nahum Sonenberg
Journal:  EMBO J       Date:  2006-06-08       Impact factor: 11.598

6.  Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines.

Authors:  Medhi Wangpaichitr; Niramol Savaraj; Johnathan Maher; Metin Kurtoglu; Theodore J Lampidis
Journal:  Mol Cancer Ther       Date:  2008-06       Impact factor: 6.261

7.  Hypoxia-inducible factor-1α (HIF-1α) promotes cap-dependent translation of selective mRNAs through up-regulating initiation factor eIF4E1 in breast cancer cells under hypoxia conditions.

Authors:  Tingfang Yi; Evangelos Papadopoulos; Patrick R Hagner; Gerhard Wagner
Journal:  J Biol Chem       Date:  2013-05-10       Impact factor: 5.157

8.  A cellular response linking eIF4AI activity to eIF4AII transcription.

Authors:  Gabriela Galicia-Vázquez; Regina Cencic; Francis Robert; Aouod Quang Agenor; Jerry Pelletier
Journal:  RNA       Date:  2012-05-15       Impact factor: 4.942

9.  Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer.

Authors:  Alexandria C Rutkovsky; Elizabeth S Yeh; Stephen T Guest; Victoria J Findlay; Robin C Muise-Helmericks; Kent Armeson; Stephen P Ethier
Journal:  BMC Cancer       Date:  2019-05-23       Impact factor: 4.430

10.  Proteogenomics connects somatic mutations to signalling in breast cancer.

Authors:  Philipp Mertins; D R Mani; Kelly V Ruggles; Michael A Gillette; Karl R Clauser; Pei Wang; Xianlong Wang; Jana W Qiao; Song Cao; Francesca Petralia; Emily Kawaler; Filip Mundt; Karsten Krug; Zhidong Tu; Jonathan T Lei; Michael L Gatza; Matthew Wilkerson; Charles M Perou; Venkata Yellapantula; Kuan-lin Huang; Chenwei Lin; Michael D McLellan; Ping Yan; Sherri R Davies; R Reid Townsend; Steven J Skates; Jing Wang; Bing Zhang; Christopher R Kinsinger; Mehdi Mesri; Henry Rodriguez; Li Ding; Amanda G Paulovich; David Fenyö; Matthew J Ellis; Steven A Carr
Journal:  Nature       Date:  2016-05-25       Impact factor: 49.962

View more
  2 in total

1.  Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma.

Authors:  Zhouhua Li; Wenjun Wang; Juan Wu; Xiaoqun Ye
Journal:  Front Med (Lausanne)       Date:  2022-08-24

2.  Integrative pan-cancer analysis and clinical characterization of the N7-methylguanosine (m7G) RNA modification regulators in human cancers.

Authors:  Chun-Ming He; Xin-Di Zhang; Song-Xin Zhu; Jia-Jie Zheng; Yu-Ming Wang; Qing Wang; Hang Yin; Yu-Jie Fu; Song Xue; Jian Tang; Xiao-Jing Zhao
Journal:  Front Genet       Date:  2022-09-26       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.